AAAAAA
Results:
1-21
|
Results: 21
Authors:
Elhilali, MM
Gleave, M
Fradet, Y
Davis, I
Venner, P
Saad, F
Klotz, L
Moore, R
Ernst, S
Paton, V
Citation: Mm. Elhilali et al., Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma, BJU INT, 86(6), 2000, pp. 613-618
Authors:
Klotz, L
Gleave, M
Goldenberg, SL
Citation: L. Klotz et al., Neoadjuvant hormone therapy: The Canadian trials, MOL UROL, 4(3), 2000, pp. 233-237
Authors:
Klotz, L
Heaton, J
Jewett, M
Chin, J
Fleshner, N
Goldenberg, L
Gleave, M
Citation: L. Klotz et al., A randomized phase 3 study of intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy, J UROL, 164(5), 2000, pp. 1573-1578
Authors:
Gleave, M
Citation: M. Gleave, Targeting anti-apoptotic genes with antisense oligodeoxynucleotides to delay progression to androgen independence, PROSTATE C, 2, 1999, pp. S15-S15
Authors:
Garnick, MB
Fair, WR
Goldenberg, SL
Gleave, M
Grignon, D
Fourcroy, J
Sufrin, G
Porterfield, H
Hart, C
Citation: Mb. Garnick et al., Fourth International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer - March 12-13, 1999 - Boston, Massachusetts - Overview consensus statement, MOL UROL, 3(3), 1999, pp. 171-174
Authors:
Gleave, M",Albertsen
Citation: Gleave, M",albertsen, Open discussion following Dr. Albertsen's presentation, MOL UROL, 3(3), 1999, pp. 191-191
Authors:
Howell, S",Civantos,"Gleave, M
Labrie, F
Fair, W
Albersten, P
D'Amico, A
Stone, N
Grignon, D
Citation: M. Howell, S",civantos,"gleave et al., Open discussion following Dr. Civantos' presentation, MOL UROL, 3(3), 1999, pp. 205-206
Authors:
Gleave, M",Stone,"Crawford, D
Labrie, F
Frangioni, J
Citation: D. Gleave, M",stone,"crawford et al., Open discussion following Dr. Stone's presentation, MOL UROL, 3(3), 1999, pp. 245-245
Authors:
Fair, W
Howell, S
Steers, W
Heston, W
Garnick, M
Gleave, M
Fourcroy, J
Citation: W. Fair et al., Open discussion following Dr. Howell's presentation, MOL UROL, 3(3), 1999, pp. 301-302
Authors:
Sufrin, G
Heston, W
Frangioni, J
Garnick, M
Howell, S
Gleave, M
Steers, W
Citation: G. Sufrin et al., Open discussion following Dr. Heston's presentation, MOL UROL, 3(3), 1999, pp. 321-321
Authors:
Gleave, M",Porterfield,"Garnick, M
Heston, W
Fair, W
Fourcroy, J
Citation: M. Gleave, M",porterfield,"garnick et al., Open discussion following Mr. Porterfield's presentation, MOL UROL, 3(3), 1999, pp. 337-337
Authors:
Gleave, M
Tolcher, A
Miyake, H
Nelson, C
Brown, B
Beraldi, E
Goldie, J
Citation: M. Gleave et al., Progression to androgen independence is delayed by adjuvant treatment withantisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model, CLIN CANC R, 5(10), 1999, pp. 2891-2898
Authors:
Vatnick, I
Brodkin, MA
Simon, MP
Grant, BW
Conte, CR
Gleave, M
Myers, R
Sadoff, MM
Citation: I. Vatnick et al., The effects of exposure to mild acidic conditions on adult frogs (Rana pipiens and Rana clamitans): Mortality rates and pH preferences, J HERPETOL, 33(3), 1999, pp. 370-374
Authors:
Gleave, M
Goldenberg, SL
Bruchovsky, N
Rennie, P
Citation: M. Gleave et al., Intermittent androgen suppression for prostate cancer: rationale and clinical experience, PROSTATE C, 1(6), 1998, pp. 289-296
Authors:
Garnick, MB
Fair, WR
Goldenberg, SL
Gleave, M
Fourcroy, J
Grignon, D
Srougi, M
Porterfield, H
Hart, C
Citation: Mb. Garnick et al., Third International Conference on Neoadjuvant Hormonal Therapy of ProstateCancer: Overview consensus statement, MOL UROL, 2(3), 1998, pp. 87-89
Authors:
Civantos, F
Tetu, B
Fair, WR
Bostwick, D
Trachtenberg, J
Pienta, KJ
Gleave, M
Citation: F. Civantos et al., Morphologic effects of neoadjuvant hormone therapy on prostate cancer - Discussion, MOL UROL, 2(3), 1998, pp. 109-109
Authors:
Rabbani, F
Garnick, MB
Goldenberg, SL
Gleave, M
Fourcroy, J
Citation: F. Rabbani et al., Randomized trial of neoadjuvant androgen ablation prior to radical prostatectomy: 24-month post-treatment PSA results - Discussion, MOL UROL, 2(3), 1998, pp. 169-169
Authors:
Goldenberg, L
Schulman, CC
Fair, WR
Gleave, M
Garnick, MB
Bostwick, D
Grignon, D
Rabbani, F
Citation: L. Goldenberg et al., Results of a European randomized study comparing radical prostatectomy andradical prostatectomy plus neoadjuvant hormonal combination therapy in stage T2-3NoMo prostatic carcinoma - Open discussion, MOL UROL, 2(3), 1998, pp. 187-187
Authors:
Garnick, MB
Gleave, M
Heston, WDW
Pienta, KJ
Citation: Mb. Garnick et al., Neither PSMA RT-PCR nor MTHFR genotype predicts PSA failure after prostatectomy - Open discussion, MOL UROL, 2(3), 1998, pp. 227-227
Authors:
Pienta, KJ
Howell, SB
Gleave, M
Garzotto, M
Citation: Kj. Pienta et al., Genomic instability and drug resistance - Open discussion, MOL UROL, 2(3), 1998, pp. 255-255
Authors:
Fair, WR
Pienta, KJ
Trachtenberg, J
Gleave, M
Bostwick, D
Garzotto, M
Garnick, MB
Citation: Wr. Fair et al., Mechanisms of androgen resistance in prostate cancer - Open discussion, MOL UROL, 2(3), 1998, pp. 263-263
Risultati:
1-21
|